{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T23:34:32Z","timestamp":1783294472052,"version":"3.54.6"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) can achieve durable responses in patients with metastatic cancers, but the long-term clonal dynamics after multiple administration and synergy with checkpoint blockade remain understudied. We present a longitudinal case study of a patient with treatment-refractory metastatic prostate cancer that achieved complete and durable tumor remission over 5-years after multiple TIL infusions and anti-PD-1 therapy. We performed longitudinal high-throughput T-cell receptor (TCR) sequencing on blood and tumor samples collected over five years to track the persistence and dynamics of TIL-derived and endogenous clonotypes. TIL-derived clonotypes exhibited sustained persistence in blood, with notable clonal expansions correlating with reduced repertoire diversity, increased clonality, and observed clinical response. Multiple TIL administration increased the patient exposure to the therapy, improving its pharmacokinetics profile over time. The third TIL infusion was followed by pembrolizumab administrations, which coincided with the re-expansion of TIL-derived clonotypes and emergence of novel clones. Serial tracking revealed clonotype stability for up to five years post-treatment. Our findings provide insights into the long-term persistence and reactivation of TIL-derived immunity and illustrate the potent synergy between adoptive transfer and PD-1 blockade by enhancing both infused and endogenous tumor-reactive T cell responses, and supporting the integration of longitudinal immunogenomic monitoring in personalized immunotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2025.1693912","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:20:57Z","timestamp":1762320057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Lucas C. M.","family":"Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Karbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Kiselicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgueni","family":"Sinelnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Gustavus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Atmaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-SITC2021.492","article-title":"492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers","volume-title":"J Clin Oncol","author":"O\u2019Malley","year":"2021"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1502905","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27604","article-title":"Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer","volume":"11","author":"Kverneland","year":"2020","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.12.010","article-title":"Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation","volume":"27","author":"Amaria","year":"2025","journal-title":"Cytotherapy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2025.08.002","article-title":"Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps","volume":"11","author":"Navarro Rodrigo","year":"2025","journal-title":"Trends Cancer"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-SITC2024.1488","article-title":"1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results","volume-title":"J Immunother Cancer.","author":"Creelan","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7890985","article-title":"Retrospective analysis of adoptive TIL therapy plus anti-PD1 therapy in patients with chemotherapy-resistant metastatic osteosarcoma","author":"Zhou","year":"2020","journal-title":"J Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e008640","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"Albarr\u00e1n Fern\u00e1ndez","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41540-024-00355-3","article-title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","volume":"10","author":"Kirouac","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2020.07.010","article-title":"T-cell repertoire analysis and metrics of diversity and clonality","volume":"65","author":"Chiffelle","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e005847","DOI":"10.1136\/jitc-2022-005847","article-title":"Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer","volume":"11","author":"Karbach","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1016\/j.jcyt.2025.03.331","article-title":"Multiple infusions of TILs expanded with IL-2\/IL-15\/IL-21 lead to an improved PK\/PD profile and long-term clinical responses in patients with cold tumors","volume":"27","author":"Arruda","year":"2025","journal-title":"Cytotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2559784","article-title":"Tumor-infiltrating lymphocytes-derived CD8 + clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma","volume":"14","author":"Arruda","year":"2025","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016712","article-title":"Sequential BCMA CAR T-cell therapy in refractory multiple myeloma","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.640166","article-title":"Short-interval sequential CAR-T cell infusion may enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti\u2013PD-1 na\u00efve and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature21676","article-title":"Effective combinatorial immunotherapy for castration-resistant prostate cancer","volume":"543","author":"Lu","year":"2017","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693912\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:20:58Z","timestamp":1762320058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693912\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":34,"alternative-id":["10.3389\/fonc.2025.1693912"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1693912","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"1693912"}}